Recurrent Miscarriage in India: Causes, Tests & Treatment

• Recurrent miscarriage usually means two or more pregnancy losses; most modern guidelines (ESHRE, ASRM, FOGSI) start a workup after two, not three.
• A treatable cause is found in roughly half of couples — antiphospholipid syndrome, thyroid disease, uterine abnormalities and parental chromosome changes are the main ones.
• Even when no cause is found (unexplained recurrent miscarriage), the next-pregnancy live-birth rate is about 60–70% with supportive care.
• Antiphospholipid syndrome is the most important treatable cause: low-dose aspirin plus heparin can lift live-birth rates from around 10–20% to 70–80%.
• Recurrent miscarriage is almost never the woman's 'fault' — it is biological, and male factors also contribute. Both partners deserve evaluation and support.
• Avoid expensive immunotherapies and routine PGT-A pushed without evidence; insist on guideline-aligned, transparent care.

Recurrent miscarriage (also called recurrent pregnancy loss) is when a person has more than one pregnancy loss. The exact number that triggers a workup has shifted over the years, which is why you may hear different definitions.

The older ASRM and WHO definition required three or more consecutive losses, on the reasoning that some couples will have two losses by chance alone. Newer evidence changed that. The ESHRE 2017 guideline and the updated ASRM 2020 position recommend starting a workup after two clinical pregnancy losses, because the chance of finding a treatable cause is already high after two, and waiting for a third loss adds avoidable grief and delay. RCOG keeps three losses for a full workup but agrees selective testing after two is reasonable. FOGSI and ISAR guidance in India broadly aligns with the two-loss threshold, especially for women of older age or with specific risk factors.

How common is it? Defined as two or more losses, recurrent miscarriage affects about 5% of couples; defined as three or more, about 1–2%. The precise figure in India is not well established, but ICMR estimates sit within the international range of roughly 1–5%.

The reason workup matters: about half of cases have an identifiable, addressable cause, treating it improves the next pregnancy's outcome, and even when no cause is found, the structured care of a dedicated clinic improves results. Importantly, recurrent miscarriage is distinct from infertility — many couples conceive easily but struggle to carry to term.

• Parental karyotype (both partners) — looks for balanced translocations and other rearrangements found in about 2–5% of couples. The parent is usually healthy, but their embryos can inherit an unbalanced arrangement. Indian labs (CDFD, Sandor, Lilac Insights, MedGenome, MapMyGenome and hospital genetics services) charge roughly Rs 4,000–8,000 per person.
• Antiphospholipid antibody screen — lupus anticoagulant, anticardiolipin (IgG/IgM) and anti-beta-2-glycoprotein I (IgG/IgM). This finds antiphospholipid syndrome, one of the most treatable causes; diagnosis needs two positive tests at least 12 weeks apart.
• Uterine cavity check — saline infusion sonography (Rs 2,500–6,000), 3D ultrasound or Hysteroscopy in India: Procedure, Costs and What to Expect (Rs 8,000–25,000) to spot a septate uterus, adhesions, polyps or submucosal fibroids. A HSG tubal patency test can outline the cavity and check the tubes at the same time, and transvaginal ultrasound is the usual first-line scan.
• Thyroid function — TSH, free T4 and anti-TPO antibodies for overt or subclinical thyroid disease and thyroid autoimmunity.
• Glucose — fasting glucose and HbA1c to catch undiagnosed diabetes or prediabetes.
• Prolactin — to detect hyperprolactinaemia.
• Selected thrombophilia tests — factor V Leiden, prothrombin gene mutation, protein C/S, antithrombin III, only when there is a personal or family history of clots or a late loss.
• Vitamin D and B12 — given how common deficiency is in Indian women.
• Case-specific extras — sperm DNA fragmentation (Rs 4,000–10,000), endometrial sampling for genital tuberculosis in high-risk settings, autoimmune markers when suspected, and natural killer cell testing (controversial, not routinely recommended).

Antiphospholipid syndrome (APS) deserves special attention because confirming it leads to treatment that dramatically improves outcomes. It is an autoimmune condition — part of the same family as systemic lupus — defined by persistent antiphospholipid antibodies plus a clinical event such as a blood clot, three or more early losses before 10 weeks, one or more losses at 10 weeks or later, or a premature birth from severe pre-eclampsia or placental insufficiency.

Diagnosis needs both clinical and laboratory criteria, with antibodies positive on two occasions at least 12 weeks apart. APS is found in roughly 5–15% of recurrent-loss couples. The antibodies promote clotting and placental dysfunction, leading to placental infarction, growth restriction and loss.

Treatment in pregnancy is low-dose aspirin 75–100 mg daily, started before or as soon as pregnancy is confirmed, combined with prophylactic-dose low-molecular-weight heparin (enoxaparin, dalteparin or tinzaparin) from confirmation through delivery and the early postpartum weeks. In India, aspirin costs about Rs 50–200 a month; LMWH about Rs 8,000–25,000 a month depending on dose and product. This regimen lifts live-birth rates from roughly 10–20% without treatment to 70–80% or higher, and is backed by ESHRE, RCOG, ASRM, ACOG and FOGSI.

One important caution: low-positive or transient antibody results that don't meet the criteria should not be treated empirically — the risk-benefit is unclear, and some Indian practices over-diagnose APS on borderline results. If your diagnosis feels uncertain, a second opinion at a recognised tertiary centre is reasonable.

Structural problems in the uterus account for about 10–20% of recurrent miscarriage, and many are surgically correctable.

Congenital malformations come from incomplete development of the Mullerian ducts. The most important is the septate uterus, where a fibrous wall divides the cavity. Hysteroscopic resection of the septum (metroplasty) improves outcomes, with live-birth rates rising from about 30–50% to 70–80% in symptomatic cases. Bicornuate, unicornuate and didelphic uteruses are diagnosed but not routinely corrected, and an arcuate uterus is now considered a normal variant.

Acquired problems include intrauterine adhesions (Asherman syndrome), submucosal fibroids that distort the cavity, polyps and chronic endometritis. Hysteroscopic removal of submucosal fibroids and polyps improves results; adhesiolysis for Asherman syndrome helps but is technically demanding and best done at specialised centres. Chronic endometritis — a low-grade infection of the lining — is increasingly recognised and treated with antibiotics.

Uterine assessment uses 3D transvaginal ultrasound (non-invasive first line), saline infusion sonography (Rs 2,500–6,000), HSG (Rs 1,500–4,000, also checks tubes), hysteroscopy (Rs 8,000–25,000, allows treatment in the same sitting) and, occasionally, MRI for complex anomalies (Rs 5,000–15,000). The right test depends on your clinical picture, availability and preference.

Hormonal causes are common, easy to find and respond well to standard treatment.

Thyroid dysfunction is one of the most common identifiable causes. Overt hypothyroidism is treated with levothyroxine aiming for TSH below 2.5 mIU/L, which improves outcomes. ESHRE, ASRM and FOGSI support the same target in subclinical hypothyroidism with recurrent loss. Anti-TPO antibody positivity raises miscarriage risk even with normal TSH; treatment here is more debated. Our deep dive on thyroid and fertility walks through the TTC targets in detail.

Diabetes — type 1, type 2 or undiagnosed glucose intolerance — raises miscarriage risk through high-sugar-induced embryopathy. Pre-conception control to HbA1c below 6.5% (ideally below 6.0%) significantly improves outcomes, and continuous glucose monitoring can help in selected cases. Good control before and during pregnancy also lowers the chance of gestational diabetes complications later.

PCOS, very common in Indian women, is linked to higher miscarriage rates through insulin resistance and hormonal imbalance; metformin in selected cases and weight optimisation may help — see our guide to PCOS and pregnancy. Hyperprolactinaemia is a less common direct cause but can disrupt ovulation; dopamine agonists (cabergoline, bromocriptine) normalise prolactin, as covered in our piece on high prolactin in women.

The old idea of 'luteal phase deficiency' is now controversial. Routine progesterone in unexplained loss is debated — the PROMISE and PRISM trials showed limited overall benefit, with possible benefit only in specific subgroups. Indian specialists often use micronised progesterone (Susten, Crinone, Naturogest) in the first trimester; for most cases this is empirical rather than strongly evidence-based.

There are two genetic angles: the parents' chromosomes and the embryo's.

Parental chromosomal abnormalities are found in about 2–5% of couples on karyotype testing — most often balanced translocations or inversions. The carrier parent is healthy because no genetic material is missing, but embryos can inherit an unbalanced arrangement, leading to miscarriage, stillbirth or an affected birth. When this is found, prenatal genetic counselling is essential to discuss recurrence risk, prenatal diagnosis (CVS, amniocentesis) and options like preimplantation genetic testing for structural rearrangements (PGT-SR), which can select chromosomally normal embryos during IVF.

Embryonic abnormalities (aneuploidy in the embryo with normal parents) cause most sporadic and recurrent miscarriages, especially as maternal age rises. The role of PGT-A in recurrent loss without a parental abnormality is debated — early enthusiasm cooled after the STAR trial showed limited improvement in cumulative live-birth rates. Current ESHRE and ASRM guidance does not recommend routine PGT-A for unexplained recurrent loss, though it may be considered in selected cases (advanced age, prior confirmed aneuploidy). PGT-A and PGT-SR add roughly Rs 50,000–200,000 per cycle on top of standard IVF.

The key reassurance: most couples with recurrent miscarriage do not have a parental chromosome problem and can achieve a healthy pregnancy through natural conception with supportive care.

• Low-dose aspirin — used in some practices despite limited evidence for unexplained loss.
• Micronised vaginal progesterone — the PRISM trial supported it specifically for women with first-trimester bleeding plus one or more previous miscarriages, leading NICE to recommend considering it in that group.
• Lifestyle and pre-conception optimisation — healthy weight, stopping smoking, limiting alcohol, correcting deficiencies and folic acid before conception all improve the biological environment for pregnancy, whether or not a cause is found.

A subsequent pregnancy after recurrent loss benefits from structured surveillance, ideally through a recurrent-loss clinic or experienced specialist.

Before conceiving: complete any indicated treatment, optimise vitamins and minerals, start folic acid 400–800 mcg daily (5 mg in selected cases) at least three months before trying, and address lifestyle and partner factors.

Early pregnancy: an early viability scan at 6–7 weeks confirms an intrauterine pregnancy and fetal heartbeat, often followed by reassurance scans every 1–2 weeks through the first trimester. Some specialists track serial beta-hCG for couples with high anxiety. Cause-specific care continues — aspirin and LMWH for confirmed APS, levothyroxine titrated to TSH below 2.5 mIU/L, strict glucose control in diabetes, and progesterone where PRISM/NICE criteria apply.

Ongoing care: first-trimester screening or NIPT, the anomaly scan at 18–22 weeks, serial growth scans if placental insufficiency is a concern, blood-pressure and urine checks (watching for pre-eclampsia), and gestational diabetes screening at 24–28 weeks (earlier if high risk).

Live-birth rates depend on the situation: confirmed APS on aspirin and LMWH reaches about 70–80%, other treatable causes improve similarly with treatment, and unexplained loss with supportive care sits around 60–70%. Many parents describe the eventual successful pregnancy — sometimes called a rainbow baby — as profound relief mixed with ongoing anxiety, so mental-health support through and after delivery matters.

• Extended-family awareness and commentary on reproductive struggles.
• Pressure to conceive quickly that leaves no room to grieve.
• Blame culture that wrongly attributes losses to the woman's food, work or behaviour.
• Gendered expectations that place fertility solely on the woman, while the male partner is rarely investigated despite male factors contributing in many cases.
• In-laws' reactions, and the absence of established rituals for early pregnancy loss in some traditions.

Initial workup can be ordered by a general gynaecologist, but a fertility centre or recurrent-loss clinic usually offers more comprehensive care. Options range from private chains (Nova, Indira, Bloom, Apollo Fertility, Cloudnine, Manipal, Birla, Cocoon, Oasis) and hospital programmes (Apollo, Fortis, Manipal, Max, Medanta) to government tertiary institutions (AIIMS, PGI Chandigarh, JIPMER, KEM Mumbai, CMC Vellore) that provide high-quality care at subsidised cost, sometimes with waiting periods.

Typical costs: consultation Rs 500–3,000; workup Rs 15,000–40,000; hysteroscopy Rs 8,000–25,000; septum resection Rs 15,000–50,000; IVF Rs 1,00,000–3,50,000 per cycle if indicated, with PGT adding Rs 50,000–2,00,000. Insurance coverage is patchy — IRDAI rules mandate some maternity cover, but much recurrent-loss workup and most assisted reproduction is out-of-pocket, though some corporate plans now include fertility benefits.

When choosing a provider, look for ESHRE-aligned or ISAR-affiliated practice, honest communication about evidence and uncertainty, willingness to discuss all options without steering you toward expensive ones, integrated mental-health support, transparent costs and easy second opinions. Be wary of providers who push repeated IVF cycles or controversial immunotherapies without a robust evidence base. You have the right to clear communication, your records, informed consent and compassionate care.

• ESHRE Guideline: Recurrent Pregnancy Loss (2017/2023 update)
• ACOG / ASRM — Evaluation and Treatment of Recurrent Pregnancy Loss
• RCOG Green-top Guideline — Recurrent Miscarriage
• NICE NG126 — Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management (progesterone, PRISM)
• Coomarasamy A et al. PRISM trial — Progesterone in women with bleeding in early pregnancy (NEJM, 2019)
• FOGSI — Federation of Obstetric and Gynaecological Societies of India